Axsome Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for the management of central nervous system (CNS) disorders. The Company works on product candidates for the treatment of resistant depression and Alzheimer's disease agitation, complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing a preclinical product candidate for CNS disorders, including chronic pain.